Heart and Vessels

, Volume 25, Issue 5, pp 363–367 | Cite as

Apelin: a novel marker for the patients with first ST-elevation myocardial infarction

  • Agnieszka M. Kuklinska
  • Bozena Sobkowicz
  • Robert Sawicki
  • Wlodzimierz J. Musial
  • Ewa Waszkiewicz
  • Swietlana Bolinska
  • Jolanta Małyszko
Original Article

Abstract

To date, only animal studies have been concerned with apelin involvement in acute myocardial ischemia. The aim of this study was to investigate apelin measurements in low-risk patients with first ST-elevation myocardial infarction (STEMI) and to assess if apelin may feature as a marker of left ventricular (LV) injury and prognosis. In 78 consecutive patients (mean age 67 ± 11.5 years, 24 women) with first STEMI treated with primary percutaneous coronary intervention, plasma apelin-36 concentrations were measured twice: on admission and on the 5th day of hospitalization. Left ventricle ejection fraction (LVEF) was applied as marker of LV injury. Composite endpoint (CEP), which included death, stroke, and recurrent ischemic event, was assessed after 1 year follow-up. On the first day, median apelin-36 concentration was 2138.5 pg/ml and on the 5th day was significantly lower, 2008.3 pg/ml (P = 0.002). There were no significant differences found in apelin-36 concentrations between patients with normal and low LVEF. In both groups significant reductions were found in apelin-36 concentrations measured in 5-day intervals (P = 0.04 and P = 0.008, respectively). After a 1-year follow-up, only one patient died and 19 patients (24.3%) had reached CEP. No difference in baseline apelin-36 concentrations were found in the group of patients who reached CEP compared with those without CEP. However, in both groups concentrations significantly decreased after 5 days (P = 0.04 and P = 0.013, respectively). Apelin-36 concentrations are reduced in lowrisk first STEMI patients during the first days regardless of the degree of LV dysfunction and prognosis.

Key words

Apelin ST-elevation myocardial infarction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chandrasekaran B, Dar O, McDonagh T (2008) The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail 10:725–732CrossRefPubMedGoogle Scholar
  2. 2.
    Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA (2006) Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 8:355–360CrossRefPubMedGoogle Scholar
  3. 3.
    De Mota N, Reaux-Le Goazigo A, El-Messari S, Chartrel N, Roesch D, Dujardin C, Kordon C, Vaudry H, Moos F, Llorens-Cortes C (2004) Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci USA 101: 10464–10469CrossRefPubMedGoogle Scholar
  4. 4.
    Ronkainen VP, Ronkainen JJ, Hänninen SL, Leskinen H, Ruas JL, Pereira T, Poellinger L, Vuolteenaho O, Tavi P (2007) Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J 21:1821–1830CrossRefPubMedGoogle Scholar
  5. 5.
    Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, Friis-Hansen L (2006) Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 133:134–138CrossRefPubMedGoogle Scholar
  6. 6.
    Dagli N, Ozturk U, Karaca I, Yavuzkir M, Koca S, Akbulut H, Balin M (2009) Adiponectin levels in coronary artery ectasia. Heart Vessels 24:84–89CrossRefPubMedGoogle Scholar
  7. 7.
    Selcuk H, Selcuk MT, Temizhan A, Maden O, Saydam GS, Ulupinar H, Dogan M, Aydin C, Topcu DI, Sasmaz A (2009) Decreased plasma concentrations of adiponectin in patients with slow coronary flow. Heart Vessels 24:1–7CrossRefPubMedGoogle Scholar
  8. 8.
    Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, Woo YJ (2004) Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110(11 suppl 1):II187–II193PubMedGoogle Scholar
  9. 9.
    Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, Sharma S, Neilson I, Webb DJ, Megson IL, Flapan AD, Newby DE (2008) Vascular effects of apelin in vivo in man. J Am Coll Cardiol 52:908–913CrossRefPubMedGoogle Scholar
  10. 10.
    Weir RA, Chong KS, Dalzell JR, Petrie CJ, Murphy CA, Steedman T, Mark PB, McDonagh TA, Dargie HJ, McMurray JJ (2009) Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail 11:551–558CrossRefPubMedGoogle Scholar
  11. 11.
    Miettinen KH, Magga J, Vuoltenaho O, Vanninen EJ, Punnonen KR, Ylitalo K, Tuomainen P, Peuhkurinen KJ (2007) Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul Pept 140:178–184CrossRefPubMedGoogle Scholar
  12. 12.
    Codognotto M, Piccoli A, Zaninotto M, Mion M, Vertolli U, Tona F, Boffa GM (2007) Evidence for decreased circulating apelin beyond heart involvement in uremic cardiomyopathy. Am J Nephrol 27:1–6CrossRefPubMedGoogle Scholar
  13. 13.
    Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M (2006) Apelin and cardiac function in hemodialyzed patients: possible relations? Am J Nephrol 26:121–126CrossRefPubMedGoogle Scholar
  14. 14.
    Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, Ben-Dor A, Fenster B, Yang E, King JY, Fowler M, Robbins R, Johnson FL, Bruhn L, McDonagh T, Dargie H, Yakhini Z, Tsao PS, Quertermous T (2003) Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108:1432–1439CrossRefPubMedGoogle Scholar
  15. 15.
    Francia P, Salvati A, Balla C, De Paolis P, Pagannone E, Borro M, Gentile G, Simmaco M, De Biase L, Volpe M (2007) Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail 9:306–309CrossRefPubMedGoogle Scholar
  16. 16.
    Simpkin J, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CCT (2007) Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 102:518–528CrossRefPubMedGoogle Scholar
  17. 17.
    Atluri P, Morine KJ, Liao GP, Panlilio CM, Berry MF, Hsu VM, Hiesinger W, Cohen JE, Joseph Woo Y (2007) Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett 12:127–138CrossRefPubMedGoogle Scholar
  18. 18.
    Sheikh AY, Chun HJ, Glassford AJ, Kundu RK, Kutschka I, Ardigo D, Hendry SL, Wagner RA, Chen MM, Ali ZA, Yue P, Huynh DT, Connolly AJ, Pelletier MP, Tsao PS, Robbins RC, Quertermous T (2008) In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol 294:H88–H98CrossRefPubMedGoogle Scholar
  19. 19.
    Li Z, Bai Y, Hu J (2008) Reduced apelin levels in stable angina. Intern Med 47:1951–1955CrossRefPubMedGoogle Scholar
  20. 20.
    Jia YX, Pan CS, Zhang J, Geng B, Zhao J, Gerns H, Yang J, Chang JK, Tang CS, Qi YF (2006) Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept 133:147–154CrossRefPubMedGoogle Scholar
  21. 21.
    Smith CC, Mocanu MM, Bowen J, Wynne AM, Simpkin JC, Dixon RA, Cooper MB, Yellon DM (2007) Temporal changes in myocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective adipocytokine apelin. Cardiovasc Drugs Ther 21:409–414CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2010

Authors and Affiliations

  • Agnieszka M. Kuklinska
    • 1
  • Bozena Sobkowicz
    • 1
  • Robert Sawicki
    • 1
  • Wlodzimierz J. Musial
    • 1
  • Ewa Waszkiewicz
    • 1
  • Swietlana Bolinska
    • 1
  • Jolanta Małyszko
    • 2
  1. 1.Department of CardiologyMedical UniversityBialystokPoland
  2. 2.Department of NephrologyMedical UniversityBialystokPoland

Personalised recommendations